Background and objectives: Uric acid (UA) has been linked to renal damage in experimental models of kidney failure. In humans, no definitive link between UA and renal function has been established, but several epidemiologic studies have suggested that higher UA levels are associated with accelerated loss of renal function, higher incidence of dialysis, and death. Many of the associations have been limited by the colinearity between UA levels and renal function. Renal transplantation is no exception, and limited information is available concerning the independent role of UA on progression of renal function in transplant recipients.
U ric acid (UA) has been implicated in the progression of chronic renal disease (1) and the incidence of ESRD in women (2) . From animal studies, there is convincing evidence of a link between UA levels and progression of renal disease (3) . Confirmation of the importance of these data in humans has been difficult (4) . There is a strong correlation between hyperuricemia and renal function; they are therefore collinear in epidemiologic investigations. It is difficult, however, to conclude that there is a direct pathogenic link between hyperuricemia and progression of renal dysfunction. In fact, in a publication by Chonchol et al. (1) , uric acid levels were found to be strongly associated with chronic kidney disease, but there was no clear association with progression of kidney disease. It might be inferred from this paper that the association of UA levels with progression of chronic kidney disease (CKD) might be dependent on the level of true baseline renal function, which is difficult to measure and thus difficult to correct for in the analysis.
The hypothesis that UA might be implicated in early renal damage, possibly even enabling the development of subsequent lesions, is certainly intriguing. Trials have been advocated to investigate the possibly preventive therapeutic implications of lowering UA levels (5) . A randomized, prospective, open-label study by Siu et al. (6) showed a significantly reduced incidence of progression of renal dysfunction in patients who were treated with allopurinol compared with the control group (without allopurinol), but it was not clearly determined in the study whether the beneficial effect observed was mainly due to allopurinol directly or to the lower UA concentrations observed in the treatment group. Moreover, a subgroup analysis showed no correlation between lower final UA concentration and progression of renal dysfunction.
If UA has a direct pathogenic effect in the progression of renal disease, then this would be particularly evident after kidney transplantation. There is preexisting damage to the kidney under such conditions, which might make the kidney more vulnerable to the effects of UA; also, medications that are used for immunosuppression may contribute to increasing (7, 8) or lowering (9) UA levels.
In 1999, Gerhardt et al. (10) showed that hyperuricemia has a significant effect on graft survival. Patients with hyperuricemia had a 5-yr graft survival rate of only 68.8% as compared with 83.3% in the patients with normouricemia, but patients with hyperuricemia also had worse baseline renal function. This study illustrates the potential bias in exploring UA as an independent predictor for the progression of kidney dysfunction. On average, patients with worse renal function will have higher UA levels; also, patients with worse renal function have a higher risk for progression to graft failure. Thus, even though UA might be a marker for the risk for graft loss, one cannot conclude that UA leads to progression of renal dysfunction from this and similar studies that did not adjust for baseline renal function (10) . In a more recent analysis, Armstrong et al. (11) concluded that hyperuricemia is associated with renal allograft dysfunction, even after correction for baseline renal function. In that study, patients who had received a transplant at least 6 mo before were recruited and then followed prospectively. It is possible that calculation of estimated GFR (eGFR) is not the best way to determine renal function in long-term renal transplant recipients. In fact, it has been shown that considerable histologic damage precedes the ultimate deterioration of renal function by many years (12) . It is therefore possible that in renal transplant patients with stable renal function, the UA level is just another indicator of histologic damage. Conversely, extensive histologic damage is rare early after transplantation; this is therefore a better setting to explore the effect of UA on renal function progression.
Recently, 3-yr follow-up data became available from the largest randomized, controlled trial in the history of kidney transplantation, the Symphony study (13) . We used data from that prospective study to address the question of whether baseline UA levels 1 mo after transplantation are associated with progression of renal dysfunction, independent of baseline renal function.
Materials and Methods
The study included renal transplant recipients (n ϭ 1645) who were enrolled in the multicenter, prospective Symphony study. The study design and main efficacy and safety data have been published elsewhere (13) . Briefly, patients were randomly assigned 1:1:1:1 to receive one of four baseline mycophenolate mofetil (MMF)-based immunosuppressive regimens: (1) Standard-dosage cyclosporine (CsA); (2) lowdosage CsA; (3) low-dosage tacrolimus; and (4) low-dosage sirolimus in conjunction with MMF, 1 g twice daily, and corticosteroids. In addition, five doses of daclizumab were given to all patients except those in the standard-dosage CsA group. Drug exposure targets and primary inclusion criteria are available from the original publication (13) .
The primary research question of our subanalysis was to test the association of early UA levels with the eGFR (estimated by the calculated creatinine clearance) at 3 yr after transplantation. Early UA levels were defined as those measured at 1 mo. Thus, for the purpose of this subanalysis, patients with graft survival of Ͻ1 mo were excluded. In addition, only a subset of the initial study population was followed out to 3 yr; therefore, our final study population consisted of patients who had 3 yr of follow-up and had available eGFR levels at this interval (n ϭ 852). One-year eGFR levels were also examined with respect to early UA levels (n ϭ 1280). UA levels were tested as both a continuous and a categorical explanatory variable to examine the effect with maximum statistical power but also to investigate a potential nonlinear relationship. Categorical groups of UA levels were defined as high, medium, and low on the basis of the top 25th percentile of levels as the high group, the middle 50th percentile of levels as the medium group, and the bottom 25th percentile of levels as the low group.
General linear models were constructed to evaluate the association of 1-mo UA levels and the response variable of 3-yr eGFR levels. Covariates for these models were selected on the basis of the outcome of univariate analyses and clinical knowledge. Covariates included in the model were donor type (categorized as living donor and as deceased donor: either expanded-criteria donor [ECD] or standard-criteria donor), immunosuppressive treatment arm, ethnicity, and baseline eGFR level (calculated at 1 mo). Models were also reformed by restricting them to patients in one of the three immunosuppressive arms with calcineurin inhibitors, because the effect of UA was considered to be potentially different in the low-sirolimus treatment arm. We also conducted a post hoc power analysis to assess the likelihood of detecting an effect of 1-mo UA level on 3-yr eGFR level, on the basis of the estimated contribution of the covariates on the r 2 value of the multivariate model.
To investigate whether early UA levels at 1 mo were maintained at additional periods after transplantation, we generated mixed models using data collected at follow-up periods at 4, 6, 8, 12, 24, and 36 wk and at 1 y after transplantation. The model was developed with baseline UA groups, time, and the group by time interaction term to evaluate the overall level during this period, and changes by group were significantly different during the period. Several forms of covariance structure were tested, including unstructured, autoregressive, compound symmetric, and toeplitz, and the final model was selected empirically on the basis of the best fit determined by the information criteria. Unadjusted comparisons were made using ANOVA models (with Tukey adjustment for multiple comparisons when testing study groups) and 2 tests for categorical variables. All analyses were performed with SAS 9.1 (SAS Institute, Cary, NC).
Results

Early UA Levels
The mean UA level at 1 mo was 5.5 mg/dl (SD 1.8 mg/dl). Patients were categorized as having high (Ն6.4 mg/dl), medium (4.4 to 6.3 mg/dl), or low (Յ4.3 mg/dl) 1-mo UA levels. Demographics and clinical characteristics of these patients are displayed in Table 1 . Patients with high UA levels at 1 mo were more likely to be obese (Ն30 kg/m 2 ), to have received a kidney from a deceased donor (particularly an ECD), and to have been initially randomly assigned to the standard cyclosporine treatment arm. In contrast, patients who were more likely to have low 1-mo UA levels included recipients of a living donation, women, and patients who were randomly assigned to the lowsirolimus treatment arm. Recipient age, obesity, and ethnicity were not statistically significantly associated with 1-mo UA level.
UA Levels over the First Year Post-Transplant
Overall level and trajectory of UA levels during the first year for the groups defined at the first month after transplantation are displayed in Figure 1 . In particular, patients in the high-UA groups maintained higher levels on average throughout the first year in which levels were collected. Results of the mixed model indicated that levels were significantly different during the first year (P ϭ 0.003) and that changes over time between groups were not significantly different (P ϭ 0.17). Differences at 1 yr were significantly different between each group comparison; P values after adjustment for multiple comparisons were as follows: High versus medium P Ͻ 0.001, medium versus low P ϭ 0.002, and high versus low P Ͻ 0.001.
Three-Year eGFR
Significant factors that were associated with 3-yr eGFR on the basis of the multivariate model were baseline (1-mo) eGFR, immunosuppressive treatment arm, and donor type (Table 2) . Patients had higher eGFR at 3 yr associated with eGFR at 1 mo. Patients who were allocated to the low-dosage sirolimus treatment arm had an estimated Ϫ8.7 ml/min lower eGFR at 3 yr relative to patients who were on standard-dosage CsA, and patients in the low-dosage tacrolimus arm had a relative decrease in eGFR of 1.8 ml/min. Patients who received an ECD transplant had Ϫ6.3 ml/min lower eGFR at 3 yr as compared with recipients of a standardcriteria donation. One-month UA level (P ϭ 0.62) and eth- Figure 1 . UA changes during the first year after transplantation by group levels defined at 4 wk. *P value reflects test between levels at 1 yr adjusted for multiple comparisons (Tukey); **P value reflects group effect from mixed model for UA groups during 1 yr; ***P value reflects group by time effect from mixed model for UA groups during 1 yr.
nicity (P ϭ 0.88) were not significantly associated with 3-yr eGFR. These results were consistent with the use of UA as a continuous variable in the multivariate model (Table 3 ). In this model, UA levels at 1 mo actually had a positive effect size (indicating that higher UA levels were associated with higher GFR levels at 3 yr), but this association was not statistically significant (P ϭ 0.97).
Results were consistent, restricting the multivariate model to only the three calcineurin inhibitor treatment arms; the effect of UA with additional adjustment for renal function was Ͻ0.01 (P ϭ 0.99). A sensitivity analysis showed similar data for the lack of association of 3-mo adjusted UA levels and 3-yr renal function. There was a NS association between 3-mo UA levels and 3-yr renal function incorporating 3-mo renal function in the model (Figure 2A ). In contrast, UA was statistically significantly associated with 3-yr renal function without adjustment for baseline renal function ( Figure 2B ). The effect of UA treated as a continuous variable at 3 mo with additional adjustment for renal function was equal to ϩ0.38 (indicating that higher UA levels were associated with higher eGFR levels) but with no statistical significance (P ϭ 0.27).
Post Hoc Power Analysis for 3-Yr eGFR
The final power of the effect of UA was based on an estimated contribution of 0.01 to the r 2 value of the model with inclusion of the previously described covariates and a cumulative r 2 value of 0.30 from the additional factors. On the basis of these assumptions, the power to detect an effect with the given sample size was 0.89. 
One-Year eGFR
The lack of association of UA levels at 1 mo was also consistent for the entire study population at the 1-yr follow up time point. The effect of UA on 1-yr renal function was not statistically significant (P ϭ 0.32) in the adjusted model and had a positive estimated effect (0.5 per mg/dl), indicating a NS but positive association between UA and renal function in the adjusted analysis.
Discussion
This subanalysis of the Symphony study indicated a lack of any significant association between UA levels and progression of renal dysfunction in the first 3 yr after transplantation. Even though patients with higher 1-mo UA levels had lower calculated eGFRs at 3 yr, this effect was entirely explained by lower baseline renal function in patients with high UA levels. In fact, correcting for baseline renal function, there was no association of worse renal function at 1 or 3 yr in patients with higher UA levels. We also wanted to make sure that UA levels later after transplantation did not affect subsequent renal function and could show that 3-mo UA levels were not associated with 3-yr renal function when correcting for 3 mo baseline renal function ( Figure 2) . We also were able to show that by the study groups that we created, we had separation in UA exposure consistent throughout the whole first year, and we would have had throughout the first year an ongoing potential injury from higher UA levels in the groups labeled as high early after transplantation (Figure 1) .
If elevated UA level were a significant risk factor for renal allograft function loss at 3 yr after transplantation, then we should have been able to detect it in a study of this size, as indicated by our post hoc power analysis. In fact, after transplantation, kidneys are sensitive to additional damage related to organ procurement factors and posttransplantation injuries from medications. Thus, this should be a sensitive model to assess the possible role of high UA levels in causing additive damage. This finding is different from those of several other reports that have hypothesized that UA may be a risk factor in progression of renal allograft dysfunction (10, 11, 14, 15) .
We developed several approaches to finding a link between UA levels and progression of renal dysfunction. In addition to using general linear and categorical models that did not show a deleterious effect of UA on 3-yr renal function when adjusting for baseline renal function, we failed to demonstrate an effect of UA on progression of renal dysfunction also when using a mixed model for repeated measures.
In another subanalysis, we tested our study hypothesis only in patients who were on calcineurin inhibitors in combination with MMF and corticosteroids, with and without daclizumab, excluding the sirolimus cohort. We even found the same lack of association between UA levels and renal function in this sensitivity analysis. This was an important analytical step, because sirolimus was also associated with lower UA levels in the Symphony study. Because the sirolimus arm was also associated with worse renal function, this could have obscured any effect of UA on renal function in the overall analysis. We corrected the main analysis for treatment arms, but this subanalysis assures us that the lack of effect of UA on renal function was not partially driven by the colinearity between renal function and low UA levels in the sirolimus arm.
Our study differs from the report by Armstrong et al. (11) in that we investigated the effect of UA early after transplantation. In the study by Armstrong et al., patients with a mean follow-up of 4 yr after transplantation were investigated. At that time point, a calculated GFR probably does not adequately reflect the intrinsic histologic damage of the kidney. It is conceivable that some patients with a good calculated GFR had significant chronic allograft injury with hyperuricemia that later precipitated to accelerated function loss (12) . For that reason, it becomes difficult to assess the effect of UA independent of renal damage in renal allograft recipients late after transplantation.
One small, non-peer-reviewed article by Akgul et al. (16) had results consistent with our findings, suggesting that there is no difference in the incidence of chronic allograft nephropathy by baseline UA levels. In that analysis, however, patients in the high-UA group started with lower serum creatinine values and the progression may not have been evident because of the small sample size and design drawbacks of the study. Thus, our study is the first to conclude with confidence that UA does not influence renal function over 3 yr after renal transplantation. It also shows how strongly renal function and UA levels are associated and why it is easy to come to the wrong conclusions about the effect of UA on renal function when inadequately correcting for renal dysfunction.
Numerous studies of patients with CKD have suggested a link between UA levels and renal dysfunction, but many were hampered by the same problem: Inadequate correction for baseline renal injury (1) (2) (3) (4) (5) 17) . Our study shows rather impressively how much of a difference in renal function at 3 yr can be explained just by the colinearity between baseline renal function and UA levels. Thus, an inadequate assessment of baseline renal injury might falsely ascribe an observed effect to UA. The only study to test the hypothesis that lowering UA pharmacologically might reduce renal injury in native kidneys could not identify UA as the only independent cause of the beneficial effect observed in a small cohort of patients (6) .
Conclusions
In renal transplant recipients, baseline UA levels do not have an independent effect on progression of renal dysfunction during the first 3 yr after transplantation. Baseline UA levels show a strong correlation with baseline renal function, and any study that inadequately adjusts for baseline renal function may ascribe effects to UA that are ascribable to worse baseline function. Similar problems might be encountered in studies of patients with CKD. Especially when investigating populations with subtle histologic kidney damage that are still functionally compensated, there is a strong possibility that the colinearity between UA levels and renal damage might lead to a false pathophysiologic implication of UA.
